Related Experiment Video
Updated: Sep 4, 2025
07:32
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.5K
Identification of a Prognostic Transcriptome Signature for Hepatocellular Carcinoma with Lymph Node Metastasis
Jie Ma1, Xue-Qin Chen1, Zuo-Lin Xiang1,2
1Department of Radiation Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Oxidative Medicine and Cellular Longevity
|July 18, 2022
Summary
This study identifies a new prognostic signature, PSG-30, to predict outcomes for hepatocellular carcinoma (HCC) with lymph node metastasis (LNM). High-risk patients may benefit from immunotherapy, with RAD54B as a key factor.
Area of Science:
- Oncology
- Genomics
- Biomarker Discovery
Background:
- Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor prognosis in lymph node metastasis (LNM) cases.
- Lack of robust biomarkers hinders accurate prognosis prediction for HCC LNM.
Purpose of the Study:
- To identify novel biomarkers for predicting prognosis in HCC with LNM.
- To develop a prognostic signature for HCC LNM patients.
Main Methods:
- Weighted gene coexpression network analysis (WGCNA) on microarray data (GSE28248, GSE40367).
- Prognostic screening using TCGA HCC cohort.
- Consensus clustering and regression analysis to identify key genes and subtypes.
Main Results:
- Developed a prognostic signature, PSG-30, for HCC LNM.
- PSG-30 identified HCC subtypes with distinct prognosis, clinicopathological features, m6A modification, ferroptosis, and immune profiles.
- RAD54B identified as an independent risk factor, correlating with tumor mutational burden and microsatellite instability.
Conclusions:
- PSG-30 effectively identifies HCC LNM patients with poor prognosis.
- High RAD54B expression suggests potential benefit from immunotherapy in HCC LNM.
- RAD54B shows pancancer relevance in LNM contexts, including breast cancer and cholangiocarcinoma.
